BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 31127020)

  • 21. The strategy of repeat stereotactic radiosurgery without whole brain radiation treatment for new brain metastases: Outcomes and implications for follow-up monitoring.
    Shen CJ; Rigamonti D; Redmond KJ; Kummerlowe MN; Lim M; Kleinberg LR
    Pract Radiat Oncol; 2016; 6(6):409-416. PubMed ID: 27687187
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320.
    Sperduto PW; Wang M; Robins HI; Schell MC; Werner-Wasik M; Komaki R; Souhami L; Buyyounouski MK; Khuntia D; Demas W; Shah SA; Nedzi LA; Perry G; Suh JH; Mehta MP
    Int J Radiat Oncol Biol Phys; 2013 Apr; 85(5):1312-8. PubMed ID: 23391814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The impact of EGFR-TKI use on clinical outcomes of lung adenocarcinoma patients with brain metastases after Gamma Knife radiosurgery: a propensity score-matched analysis based on extended JLGK0901 dataset (JLGK0901-EGFR-TKI).
    Yomo S; Serizawa T; Yamamoto M; Higuchi Y; Sato Y; Shuto T; Akabane A; Jokura H; Kawagishi J; Aoyama H
    J Neurooncol; 2019 Oct; 145(1):151-157. PubMed ID: 31487030
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer.
    Halasz LM; Uno H; Hughes M; D'Amico T; Dexter EU; Edge SB; Hayman JA; Niland JC; Otterson GA; Pisters KM; Theriault R; Weeks JC; Punglia RS
    Cancer; 2016 Jul; 122(13):2091-100. PubMed ID: 27088755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study.
    Zhai X; Li W; Li J; Jia W; Jing W; Tian Y; Xu S; Li Y; Zhu H; Yu J
    Radiat Oncol; 2021 Dec; 16(1):233. PubMed ID: 34865626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Salvage whole brain radiotherapy or stereotactic radiosurgery after initial stereotactic radiosurgery for 1-4 brain metastases.
    Liu Y; Alexander BM; Chen YH; Horvath MC; Aizer AA; Claus EB; Dunn IF; Golby AJ; Johnson MD; Friesen S; Mannarino EG; Wagar M; Hacker FL; Arvold ND
    J Neurooncol; 2015 Sep; 124(3):429-37. PubMed ID: 26108659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for up to 10 brain metastases.
    Lester-Coll NH; Dosoretz AP; Magnuson WJ; Laurans MS; Chiang VL; Yu JB
    J Neurosurg; 2016 Dec; 125(Suppl 1):18-25. PubMed ID: 27903191
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Arbour KC; Kris MG; Riely GJ; Ni A; Beal K; Daras M; Hayes SA; Young RJ; Rodriguez CR; Ahn L; Pao W; Yu HA
    Cancer; 2018 Jan; 124(1):105-109. PubMed ID: 28940498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Epidermal Growth Factor Receptor (EGFR) Inhibitors and Radiation in the Management of Brain Metastases from EGFR Mutant Lung Cancers.
    Khandekar MJ; Piotrowska Z; Willers H; Sequist LV
    Oncologist; 2018 Sep; 23(9):1054-1062. PubMed ID: 29703765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Whole brain radiation therapy plus focal boost may be a suitable strategy for brain metastases in SCLC patients: a multi-center study.
    Ni M; Jiang A; Liu W; Sheng Y; Zeng H; Liu N; Gao Q; Wang Y; Yu J; Yuan S
    Radiat Oncol; 2020 Mar; 15(1):70. PubMed ID: 32213185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of stereotactic radiosurgery with and without whole-brain radiotherapy for the treatment of newly diagnosed brain metastases.
    Hall MD; McGee JL; McGee MC; Hall KA; Neils DM; Klopfenstein JD; Elwood PW
    J Neurosurg; 2014 Dec; 121 Suppl():84-90. PubMed ID: 25434941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].
    Chen L; Fu M; Zhou J; Yao Y; Zhou J
    Zhongguo Fei Ai Za Zhi; 2019 May; 22(5):312-318. PubMed ID: 31109441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy.
    Caballero JA; Sneed PK; Lamborn KR; Ma L; Denduluri S; Nakamura JL; Barani IJ; McDermott MW
    Int J Radiat Oncol Biol Phys; 2012 May; 83(1):303-9. PubMed ID: 22079723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of Stereotactic Radiosurgery in Elderly and Very Elderly Patients With Brain Metastases to Limit Toxicity Associated With Whole Brain Radiation Therapy.
    Chen L; Shen C; Redmond KJ; Page BR; Kummerlowe M; Mcnutt T; Bettegowda C; Rigamonti D; Lim M; Kleinberg L
    Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):939-947. PubMed ID: 28602418
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery.
    Yang WC; Xiao F; Shih JY; Ho CC; Chen YF; Tseng HM; Chen KY; Liao WY; Yu CJ; Yang JC; Kuo SH; Cheng JC; Yang PC; Hsu FM
    Radiother Oncol; 2018 Feb; 126(2):368-374. PubMed ID: 29111173
    [TBL] [Abstract][Full Text] [Related]  

  • 36. EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis.
    Soon YY; Leong CN; Koh WY; Tham IW
    Radiother Oncol; 2015 Feb; 114(2):167-72. PubMed ID: 25583566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcome and prognostic factors in single brain metastases from small-cell lung cancer.
    Bernhardt D; Adeberg S; Bozorgmehr F; Opfermann N; Hörner-Rieber J; König L; Kappes J; Thomas M; Unterberg A; Herth F; Heußel CP; Warth A; Debus J; Steins M; Rieken S
    Strahlenther Onkol; 2018 Feb; 194(2):98-106. PubMed ID: 29085978
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases.
    Patil CG; Pricola K; Sarmiento JM; Garg SK; Bryant A; Black KL
    Cochrane Database Syst Rev; 2017 Sep; 9(9):CD006121. PubMed ID: 28945270
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.
    Hyun DG; Choi CM; Lee DH; Kim SW; Yoon S; Kim WS; Ji W; Lee JC
    PLoS One; 2020; 15(4):e0231546. PubMed ID: 32298306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A multi-institutional study of factors influencing the use of stereotactic radiosurgery for brain metastases.
    Hodgson DC; Charpentier AM; Cigsar C; Atenafu EG; Ng A; Bahl G; Zadeh G; San Miguel J; Menard C
    Int J Radiat Oncol Biol Phys; 2013 Feb; 85(2):335-40. PubMed ID: 22704984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.